India's Sun Pharmaceutical Industries has received approval from the U.S. Food and Drug Administration to market alendronate sodium tablets, the generic version of Merck & Co's  Fosamax.

Fosamax tablets, used for treating women with the bone-thinning disease osteoporosis, have annual sales of about $560 million in the United States, said a company statement on Friday. Sun said the drug would reach the U.S. market shortly.